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Abstract: The tumor microenvironment is known to play a pivotal role in driving cancer
progression and governing response to therapy. This is of significance in pancreatic cancer
where the unique pancreatic tumor microenvironment, characterized by its pronounced
desmoplasia and fibrosis, drives early stages of tumor progression and dissemination, and
contributes to its associated low survival rates. Several molecular factors that regulate
interactions between pancreatic tumors and their surrounding stroma are beginning to be
identified. Yet broader physiological factors that influence these interactions remain unclear.
Here, we discuss a series of preclinical and mechanistic studies that highlight the important
role chronic stress plays as a physiological regulator of neural-tumor interactions in driving
the progression of pancreatic cancer. These studies propose several approaches to target
stress signaling via the β-adrenergic signaling pathway in order to slow pancreatic tumor
growth and metastasis. They also provide evidence to support the use of β-blockers as
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a novel therapeutic intervention to complement current clinical strategies to improve cancer
outcome in patients with pancreatic cancer.
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1. Introduction
The tumor microenvironment (TME) is increasingly recognized for its crucial role in influencing
cancer progression [1] and response to therapy [2,3]. The close spatial proximity between pancreatic
cancer cells and the dense stromal cell population within the pancreas creates an environment that
favors pancreatic cancer cell proliferation and dissemination, and impedes access of chemotherapeutic
drugs [3–6]. These factors compound the issues of a disease that is frequently diagnosed late, resulting
in an exceptionally poor five-year survival rate of 5% [7].
Similar to many other tumor types, the pancreatic TME contains many cellular and structural
components such as tumor-associated macrophages and blood and lymphatic vasculature that contribute
to the trajectory of pancreatic cancer progression. However, the pancreatic TME also contains
unique features such as the presence of pancreatic stellate cells (PSCs), which contribute to the
extensive desmoplastic reaction and fibrosis associated with pancreatic cancer [8,9], and a dense
network of nerve fibers that can interact closely with tumor cells to affect tumor growth and provide a
pathway for tumor cell dissemination [10–13]. While the molecular factors that regulate TME-tumor
cell interactions in pancreatic cancer are beginning to be elucidated, the physiological factors that
regulate this interaction are unclear. Here, we describe accumulating evidence that demonstrate
the importance of peripheral sympathetic nervous system (SNS) activation of β-adrenergic receptor
signaling in influencing pancreatic cancer progression. We discuss the potential use of β-blockers
as a novel treatment strategy to block the adverse effects of SNS signaling, and as an adjuvant
therapy to complement existing treatment modalities to improve the quality of life of patients with
pancreatic cancer.
2. Nerve Fibers Are a Component of the Pancreatic Tumor Microenvironment
The pancreatic microenvironment consists of a broad repertoire of cellular and structural components.
This includes glandular epithelial cells in the exocrine acini, that are responsible for the secretion of
digestive enzymes, and the endocrine Islet of Langerhans that are involved in hormone secretion [14].
Due to its central role in enzyme and hormone production, the pancreas also contains a dense network
of blood vessels to allow for efficient, systemic release of its products into circulation. Tumors can
arise from different regions within the pancreas. However, they typically arise from the exocrine
compartment which accounts for more than 95% of pancreatic cancers [15]. During the development
of a tumor, there is an influx of immune cells into the pancreatic TME, including macrophages that
are recruited by tumor cells to promote immunosuppression, tumor vascularization, and metastasis [16].
In addition to these common stromal components, the pancreatic TME also contains several unique
components that may contribute to the aggressive nature of pancreatic cancer [17]. The presence of
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myofibroblast-like PSCs have been shown to support the progression of pancreatic cancer [5,6,9,18]
while the particularly high levels of hyaluronic acid, a component of extracellular matrix, has also been
demonstrated to impede the delivery of therapeutic agents [19]. Additionally, the extensive network
of nerve fibers from the autonomic nervous system forms an integral part of the unique architecture
of the pancreatic microenvironment and may also influence cancer progression [20,21]. These nerve
fibers include the sympathetic splanchnic nerves, vagus nerve and sensory nerve fibers [22]. Under
normal physiological conditions, these nerve fibers work together to regulate digestive enzyme secretion
and endocrine hormone secretion [22–26]. In particular, activation of fibers of the peripheral SNS,
which innervate many areas of the pancreas including areas of exocrine and endocrine tissue as well
as blood vessels [21], has been shown to regulate endocrine hormone secretion [25,26] and pancreatic
norepinephrine content [27]. Pancreatic tumors are often associated with hyperinnervation, which occurs
early in hyperplasia before the transition into overt, malignant disease [28], and is often linked to elevated
levels of neuroplasticity markers in the pancreatic TME [11,29,30]. Despite their normal physiological
functions, these nerve fibers can also serve as an alternative route for the dissemination of tumor cells,
whereby tumor cell invasion into nerve fibers (perineural invasion) [10,12,13,31] is associated with
neuropathic pain, a common characteristic of pancreatic cancer [12].
Physiological activation of the SNS results in the release of the neurotransmitter norepinephrine
from the postganglionic nerve fiber terminus [32] into the pancreas which leads to the elevation of
intrapancreatic norepinephrine content [27]. Norepinephrine release from nerve fibers and the adrenal
medulla may also be induced by nicotine via activation of nicotinic acetylcholine receptors [33]. Both
tumor cells and pancreatic stromal cells express SNS-responsive adrenergic receptors suggesting that
SNS signaling could potentially impact the progression of pancreatic cancer (Figure 1). Autocrine
response to neurotransmitters is also plausible as norepinephine and epinephrine are synthesized and
released by pancreatic duct epithelial cells and pancreatic cancer cells [34,35]. Although the relationship
between stress and clinical cancer progression remains unclear, a meta-analysis of over 126 studies
spanning 10 different cancer types showed that stress-related psychosocial factors such as depression
and stress-prone personality were associated with higher cancer incidence and poor cancer survival [36].
While pancreatic cancer was not specifically analyzed in this study, a similar association between stress
and pancreatic cancer progression is possible, suggested by evidence that that shows relative levels of
distress, depression and anxiety to be highest amongst patients with pancreatic cancer [37–39].
Stress-induced SNS activation elevates intra-pancreatic catecholamine levels (norepinephrine, NE;
epinephrine, EPI), which can bind β-adrenergic receptors present on tumor cells to promote tumor
cell proliferation and invasion. Stress-induced β-adrenergic signaling may also have effects on various
stromal cells present in the pancreatic tumor microenvironment, such as tumor-associated macrophages
(TAMs) and pancreatic stellate cells (PSCs) to enhance their tumor supporting functions. These effects
collectively result in increased primary tumor growth, tumor cell dissemination and metastasis to distant
organs. The adverse effects of stress signaling can be targeted through the use of β-blockers. MMP:
Matrix metalloproteinases.
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Figure 1. Neural regulation of pancreatic cancer. 
3. Orthotopic Preclinical Models Recapitulate Tumor-Stromal Interactions 
The significant contribution of the TME to pancreatic cancer progression described above highlights 
the importance of using preclinical disease models that faithfully recapitulate tumor-stromal interactions. 
The significant impact of adrenergic signaling on pancreatic cancer cell behavior (proliferation [40,41], 
motility [40,42] and invasion [40,42,43]) has been studied in vitro. A few pre-clinical studies have 
investigated the effect of stress on pancreatic cancer progression in vivo, however these were conducted 
using subcutaneous models that do not replicate the complexity of the pancreatic TME [44,45]. 
Therefore, in order to fully recapitulate the comprehensive effects of stress-induced adrenergic signaling 
on the pancreatic TME and the possible effect this may have on cancer progression, the use of orthotopic 
cancer models is needed. 
There is considerable evidence that tumors grown ectopically behave differently to their orthotopic 
counterparts. Comparative microarray analysis of a panel of human pancreatic cancer cell lines revealed 
that gene expression differed greatly when tumor cells were grown in vitro compared to in vivo, or when 
tumor cells were implanted ectopically into subcutaneous tissue compared to orthotopically into the 
pancreas, demonstrating the importance of the organ microenvironment in affecting tumor cell gene 
expression [46]. In addition, co-implantation studies revealed the importance of stromal cells in 
modulating tumor growth [47]. Co-implantation of tumor cells with organ-specific stromal cells into 
ectopic sites significantly enhanced vascular development and affected the kinetics of tumor growth 
compared to tumor cells injected alone, further highlighting the impact of the stromal environment in 
regulating tumor progression [47]. This is supported by numerous studies that demonstrated the role of 
an orthotopic organ microenvironment in conferring distinct growth and therapeutic response  
profiles [48–52]. Subcutaneous tumors exhibited greater sensitivity to treatment than orthotopic tumors 
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obtained from the same tumor cell line [52,53]. In contrast to orthotopic preclinical models, ectopic
mouse models of cancer rarely result in metastasis, as demonstrated in studies of colon cancer [54],
gallbladder carcinoma [55], prostate cancer [56,57], renal cell carcinoma [58] and pancreatic cancer [59].
These differences in cancer progression between orthotopic and ectopic models may be attributed to
the lack of appropriate stromal cells to drive metastasis, such as pancreatic stellate cells which in
the context of pancreatic cancer have been shown to aid in tumor cell invasion and metastasis [5,6].
Collectively, these studies emphasize the importance of studying pancreatic cancer in its natural, or
orthotopic, environment to ensure the clinical relevance of findings and to allow for rapid translation.
Several orthotopic mouse models of pancreatic cancer are well established. These involve either the
injection of tumor cell suspensions [59–61] or surgically transplanting pancreatic tumor fragments into
the pancreas [62,63]. However, prior to the development of in vivo imaging technologies, non-invasive
monitoring of primary tumor growth and dissemination in these models was challenging until the late
stages of disease, therefore restricting the development of diagnostics and the development of treatment
options to the very late stages of pancreatic cancer when disease had already progressed significantly.
As a result, non-orthotopic models using subcutaneous injection of pancreatic cancer cells into the
flank were often used to allow for easy monitoring of tumor growth. Recent advances in imaging
technology using ultrasound and fluorescence now allow for non-invasive assessment of tumor growth
in the pancreas [64]. Furthermore, optical bioluminescence imaging of tumor cells that are transduced to
express Firefly or Renilla luciferase has also emerged as a highly sensitive alternative to fluorescence and
ultrasound imaging to allow real-time monitoring of pancreatic tumor development and metastasis [6,65].
In order to recapitulate more accurately the tumor-stromal interactions that are present in the tumors of
patients, patient-derived xenograft (PDX) models—where small tumor fragments from excised patient
tumor samples are engrafted in immune-deficient mice—are now increasingly used in the studies of
various cancer types [66–70]. These PDX models using either ectopic or orthotopic tumors have been
shown to be genetically stable over several in vivo passages and have been used for the identification of
biomarkers to predict therapeutic response [71] and the evaluation of combination therapy efficacy [72].
4. Stress Regulates Pancreatic Cancer Progression
These various lines of evidence—that stress-induced SNS signaling promotes the progression
of a number of cancers [73–76], and that the pancreatic microenvironment is responsive to SNS
signaling—spurred a series of pre-clinical studies to investigate whether chronic stress promotes
pancreatic cancer progression in the orthotopic setting. In order to examine the impact of chronic
stress on pancreatic cancer progression in tumors grown in the appropriate stroma, we used a mouse
model of pancreatic cancer whereby Panc-1 tumor cells were implanted into the tail of the pancreas of
nude mice [65]. To physiologically activate SNS signaling pathways, mice were subjected to repeated
restraint stress and longitudinal bioluminescence imaging was used to track the effect of stress on cancer
progression [77]. Repeated restraint is a frequently used experimental method that increases levels of
stress neurotransmitters and hormones [73,74,78]. Chronic stress significantly increased primary tumor
growth, an effect that was detectable 21 days after tumor cell implantation and eventually resulted
in >10-fold increase in tumor size 42 days post tumor cell implantation. This was associated with
a significant increase in primary tumor mass in stressed mice at the conclusion of the experiment.
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Interestingly, such stress-enhanced growth of the primary tumor was not observed in previous studies
using orthotopic models of breast cancer [73], which suggests the sensitivity of primary tumor growth to
chronic stress may differ between cancer types.
To date, surgical resection of the primary tumor remains the main curative treatment option for
pancreatic cancer. In order to recapitulate standard clinical treatment, we resected the orthotopic
pancreatic tumor and used bioluminescence imaging to ensure that tumor-free margins (R0) were
obtained [77]. At the time of resection, we examined the adjacent pancreas for disseminated disease.
Bioluminescence imaging revealed that chronic stress also induced local dissemination of tumor cells
into adjacent, normal, pancreatic tissue. In the clinical context, it is plausible that these cells may seed
recurrence if not removed by total pancreatectomy. Additional histological analyses will be required
to determine if these cells were present in the pancreatic parenchyma or were transiting through blood
or lymphatic vessels. To the extent that chronic stress drives dissemination of tumor cells in patients
with pancreatic cancer, these observations provide a possible explanation for the high levels of tumor
recurrence in the clinical setting, even after successful R0 resection of the primary tumor. Consistent
with the concept that stress drives tumor cell dissemination, stress also increased distant metastasis to
liver, spleen and lymph nodes within the gastrointestinal tract compared to control mice [77]. Similar
stress-enhanced metastasis was observed in our earlier studies using an orthotopic model of breast
cancer [73] and in mouse models of ovarian cancer [74], suggesting metastatic and invasive behavior
of tumor cells across multiple cancer types are sensitive to stress signaling. This is of particular
significance in pancreatic cancer as local recurrence and distant metastasis are common in patients,
even after potential curative resection of the primary tumor [79,80]. Our findings suggest that stress
signaling could potentially drive local recurrence of pancreatic cancer and distant metastasis, leading to
poor outcomes for patients.
The effects of stress on pancreatic cancer progression are not unique to the restraint paradigm, but
have been observed using other experimental situations that activate the conserved stress response.
Exposure to sound stress activated neural signaling as indicated by elevated systemic epinephrine
and enlarged adrenal glands, and increased pancreatic tumor volume in an ectopic pancreatic cancer
model [44]. Another social stress paradigm using twice weekly changes in cage composition similarly
promoted pancreatic tumor growth [45]. Chronic stress also drives the progression of other cancer types
including breast cancer [73], prostate cancer [75], ovarian cancer [74,78,81], and acute lymphoblastic
leukemia [76], highlighting the generalizability of stress effects on cancer progression. These data
show that chronic stress increases the growth and dissemination of pancreatic cancer and suggest that
sensitivity to stress signaling may be a general phenomenon that impacts many tumor types. Collectively,
these findings also suggest that inhibiting stress signaling may be a novel strategy to slow disease
progression and improve the condition of patients with pancreatic cancer.
5. Stress Acts through a β-Adrenergic Signaling Pathway
Mechanistic intervention studies have characterized a key role for β-adrenergic receptor signaling
in the effects of stress on pancreatic cancer progression. Stress-induced activation of the SNS leads
to the release of catecholaminergic neurotransmitters, norepinephrine and epinephrine, systemically
from the adrenal glands or locally from postganglionic sympathetic nerve fiber termini within the
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pancreatic microenvironment. These catecholamines can then bind to α- and β-adrenergic receptors
to elicit cellular effects [32]. Human pancreatic cancer cell lines including Panc-1, BxPC-3, HDPE6-C7,
MIA Paca-2 and PC-2, and stromal cells found in the pancreas including macrophages, fibroblasts
and endothelial cells express β-adrenergic receptors [41,45,82–90]. We showed that treatment of
mice with the non-selective β-antagonist, propranolol, reduced the effect of stress on primary tumor
growth and tumor cell dissemination into the adjacent normal pancreas [77]. To minimize the induction
of stress by daily subcutaneous injection and handling, these studies used subcutaneously implanted
osmotic minipumps for continuous drug administration. The findings indicate that β-adrenergic receptor
signaling is necessary for the effects of chronic stress on pancreatic cancer and provide evidence that
β-blockade may be used to pharmacologically block the adverse effects of stress.
Consistent with a key role for β-adrenergic signaling in pancreatic cancer progression, in vitro
and in vivo studies have shown that activation of β-adrenergic receptor signaling is sufficient to drive
pancreatic cancer progression in ectopic models. Activation of β-adrenergic receptors by isoproterenol,
a non-selective β-adrenergic receptor agonist, promoted pancreatic cancer cell proliferation
in vitro [83,91] and treatment with isoproterenol significantly promoted tumor growth in an ectopic
mouse model of pancreatic cancer [86]. To examine if β-adrenergic receptor signaling is sufficient
to drive pancreatic cancer progression in the context of the pancreatic stroma, we treated mice
bearing orthotopic pancreatic tumors with isoproterenol during the period of tumor development.
Isoproterenol significantly increased primary tumor mass and increased dissemination of tumor cells
into the adjacent pancreas and to distant tissues. These findings revealed that β-adrenergic signaling
alone was sufficient to mimic the effect of stress on pancreatic cancer progression [77]. Other studies
similarly documented the critical role ofβ-adrenergic signaling in driving the progression of other cancer
types [73,74,76,92,93].
6. β-Adrenergic Signaling Drives Tumor Cell Invasion
Tumor cell invasion plays a key role in pancreatic cancer recurrence and metastasis [79,80,94].
We therefore sought to determine if the effects of β-adrenergic signaling on cancer invasion within
the pancreatic microenvironment are due to direct effects on tumor cells or through the effects of
β-adrenergic signaling to the pancreatic microenvironment. A number of studies have shown that in vitro
activation ofβ-adrenergic receptors promotes the invasiveness of numerous human pancreatic cancer cell
lines including Panc-1, MIA Paca-2 and BxPC-3 [40,43,91]. Consistent with those studies, we found
that treatment with isoproterenol increased basement membrane invasion by Panc-1 pancreatic cells in a
dose-dependent manner, and that these effects were blocked by the β-blocker propranolol.
It is well established that matrix metalloproteinases (MMPs) facilitate tumor cell invasion by
degrading the surrounding extracellular matrix [95–97]. Previous studies demonstrated that stress was
associated with increased MMP expression in tumors of mice [73,74] and in patient tumor samples [98].
Therefore, it is plausible that β-adrenergic signaling mediates stress effects on pancreatic cancer cell
invasion and metastasis by upregulating MMP expression either by tumor cells or by stromal cells
in the pancreatic TME. Quantitation of transcript levels in cultured tumor cells demonstrated that
isoproterenol upregulated MMP2 and MMP9 expression by two-fold and four-fold, respectively [77],
with the endogenous catecholamine norepinephrine shown to have similar effects [43]. To confirm
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the effects of stress-enhanced MMP expression in vivo, we further analyzed the effect of chronic
restraint stress on MMP expression in tumor and stromal cells in primary orthotopic pancreatic tumors.
The impact of stress on the expression of both MMP2 and MMP9 in tumors in vivo was far greater
than that observed in vitro. Stress selectively increased MMP9 expression in tumor cells („50-fold
compared to non-stressed mice) while stress enhanced MMP2 expression in cells from the stromal
compartment (>100-fold compared to non-stressed mice) [77]. These findings indicate that the effects
of SNS signaling during stress are not limited to pancreatic cancer cells alone, but that β-adrenergic
regulation of the pancreatic TME may be influential in driving cancer invasion and distant metastasis
(Figure 1). Consistent with these findings from orthotopic mouse models, tumor samples from patients
with pancreatic ductal adenocarcinoma have also shown differential MMP expression in the tumor
and stromal cell compartments. Histological analyses found that MMP2 expression was elevated in
pancreatic stroma compared to neoplastic epithelium [99]. It was also found that MMP2 activity
increased with pancreatic tumor grade [100], highlighting the important role of MMP2 in the progression
of pancreatic cancer. Although it is essential to characterize the effect of stress on MMP expression and
tumor cell invasion in clinical samples, this line of evidence suggests that stress-induced β-adrenergic
signaling may enhance tumor cell dissemination by also affecting stromal cell components within the
TME to facilitate tumor cell invasion.
It will also be important to determine which components of the pancreatic TME are responsible
for modulating stress-enhanced protease production. One candidate is tumor-associated macrophages
which express β-adrenergic receptors [101] and modulate gene expression in response to β-adrenergic
signaling [73,98,102]. Given that tumor-associated macrophages induce immunosuppression, promote
metastasis and impair response to treatment [103,104], it is plausible that stress either promotes
macrophage infiltration into pancreatic tumors or changes the phenotype of tumor-associated
macrophages to mediate stress-enhanced effects on MMP expression and cancer progression. Consistent
with this hypothesis, our earlier studies of breast cancer have demonstrated that stress promotes
macrophage recruitment to primary tumors, which was necessary for stress-enhanced metastasis [73].
Another stromal cell type that has been implicated in the progression of pancreatic cancer is PSCs,
which have been described as a source of MMPs and other pro-metastatic molecules [105]. PSCs
promote desmoplasia, a characteristic feature in pancreatic cancers, by increasing the production of
extracellular matrix molecules including collagen and fibronectin [8,9]. Interactions between PSCs
and tumor cells invoke a positive feedback loop to enhance the proliferation of either cell type and
induce regional metastasis of pancreatic cancer cells in mice [5,9]. Additionally, PSCs can disseminate
together with pancreatic cancer cells to distant organs [106], suggesting PSCs may also assist to establish
metastatic outgrowths in distant organs. The effect of stress signaling on PSCs remains unknown. PSCs
are similar to hepatic stellate cells in their morphology and function [107,108], suggesting that PSCs
may be similarly responsive to NE-enhanced proliferation as observed for hepatic stellate cells [109].
Considering the pivotal role of PSCs in pancreatic cancer progression, it is essential to examine the
impact of stress on PSCs themselves, and on tumor cell-PSC interactions in the effects on pancreatic
cancer progression. Together, these findings suggest that regulation of tumor-stromal interactions to
elevate protease production may be one mechanism by which stress promotes the dissemination of
pancreatic cancer cells.
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7. Stress Regulates Tumor Cell Proliferation and Apoptosis
In addition to its effects on tumor cell invasion, stress may also drive pancreatic tumor growth by
increasing the rate of tumor cell proliferation. Endogenous stress neurotransmitters were demonstrated
to promote pancreatic cancer cell proliferation in vitro [40,41] via the activation of β-adrenergic
signaling [83,86,91]. Several signaling pathways downstream of β-adrenergic receptors have been
proposed to mediate stress-enhanced tumor cell proliferation, including activation of HIF-1α-dependent
transcription [44] and activation of the ERK/MAPK pathway [86]. It is also noteworthy that
stress-enhanced tumor growth was not limited to the orthotopic model [77], but was similarly observed
in ectopic models of pancreatic cancer [45,86], suggesting that stress may act directly on pancreatic
cancer cells to modulate cell proliferation.
In addition to promoting tumor cell proliferation, stress may promote tumor growth by inhibiting
apoptosis of tumor cells. Several in vitro studies have shown that activation of β-adrenergic
signaling pathways protects tumor cells against cell death [78,110,111]. Additionally, inhibiting
β-adrenergic signaling to pancreatic cancer cells induced apoptosis by suppressing the Ras/Akt/NFκB
signaling pathway [41,85]. Similar findings were also reported in studies of hemangioma [112],
neuroblastoma [113], melanoma [114], and gastric cancer [115]. However, the effectiveness of
β-blockade in inducing apoptosis was inconsistent in ectopic mouse models of pancreatic cancer [44,86],
which may be attributed to cell-intrinsic differences in β-blocker sensitivity in the pancreatic cancer cell
lines used. Further investigation to clarify the effect of β-blockers in different pancreatic cell lines, and
in the context of the pancreatic TME using orthotopic models and samples from pancreatic patients who
previously used β-blockers (e.g., for co-morbid hypertension) will provide additional insights into the
effect of stress signaling on tumor cell proliferation and apoptosis.
8. Translation of β-Blockers for the Treatment of Pancreatic Cancer
To effectively translate β-blockers for the treatment of pancreatic cancer, it will be essential to
determine the treatment regimen and to define which patients will most benefit. β-blockers, commonly
used for the treatment of hypertension in the clinical setting, may also be used in the adjuvant setting
to improve the efficacy of existing chemotherapy regimens or in patients with unresectable tumors.
For patients with advanced stage pancreatic cancer, an unresectable tumor often restricts the choice of
treatment to chemotherapy. Gemcitabine is at the core of the standard-of-care chemotherapy regimen for
pancreatic cancer and results in an average 5-8 months prolongation of survival [116–119]. Recent trials
of several combination therapies for pancreatic cancer including gemcitabine combined to the epidermal
growth factor receptor (EGFR) antagonist erlotinib [120], FOLFIRINOX (a combination of oxaliplatin,
irinotecan, leucovorin and flurouracil) [121], or gemcitabine combined with the albumin-bound taxane
derivative nab-paclitaxel [122] have shown improvement of overall survival from weeks to months.
However, these strategies have been accompanied by increased side effects and toxicity such as
peripheral neuropathy. Therefore, combination therapies with better efficacy and safety profiles are
urgently needed for the treatment of pancreatic cancer.
The preclinical studies presented here suggest that β-blockers could be used to complement existing
chemotherapeutic strategies to improve cancer outcome in patients with pancreatic cancer [44,77,86].
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While a small retrospective study did not support this concept [123], positive results were obtained in
a recent prospective trial [124]. The study was a randomized, open-label, single-center clinical trial
to compare the effectiveness of propranolol plus etodolac, a COX-2 inhibitor, in combination with
gemcitabine plus nab-paclitaxel [124]. Addition of the β-blocker to the treatment strategy significantly
improved the median overall survival by 7.7 months (9.3 months in chemotherapy arm, n = 17, vs.
17 months in chemotherapy + β-blocker, n = 20). Furthermore, β-blockade also reduced treatment
complications including weight loss and peripheral neuropathy. While further studies are required in
order to conclusively demonstrate the beneficial effects of β-blockers on clinical cancer outcome, these
findings support the feasibility of using β-blockers to complement current chemotherapeutic agents to
improve overall survival. As they are safe and well characterized drugs, β-blockers may have additional
benefits of reducing side effects without the risk of increased toxicity.
Several epidemiological studies have shown the use of β-blockers at the time of cancer diagnosis
to be associated with improved cancer outcome in a number of solid cancer types such as breast
cancer [125–128], prostate cancer [129], melanoma [130,131], ovarian cancer [132] or non-small-cell
lung cancer [133]. In addition to targeting the adverse effects of chronic stress, β-blockers may be
useful to counter diagnosis-related anxiety and surgical stress that accompanies tumor resection. Stress
is a frequent consequence of cancer diagnosis, particularly in the case of pancreatic cancer where patients
are often faced with an extremely poor prognosis [37–39]. As pancreatic cancer cells and stromal cells
express β-adrenergic receptors [41,45,82–86], it is therefore plausible that the use of β-blockers could
potentially improve pancreatic cancer outcome by attenuating the effects of stress via the inhibition of
SNS signaling.
An additional window of opportunity to block stress signaling may be during surgical resection of
pancreatic tumors. The perioperative period is a window of time when patients are particularly vulnerable
to physiological stress signaling, and accumulating experimental and clinical evidence suggests that
surgical stress may drive long-term cancer recurrence [134]. In addition to complementing existing
chemotherapeutic agents, β-blockers could be given to pancreatic cancer patients prior to surgical
resection to reduce the effect of elevated neurotransmitter levels and limit inflammation with the goal
of improving cancer outcomes. It is possible that perioperative β-blockade may additionally modulate
the microenvironment of metastatic targets to limit metastatic outgrowth of circulating tumor cells as a
result of surgery.
9. Conclusions
Increasing evidence indicates that stress signaling drives pancreatic cancer progression [44,45,77],
with tumor cell invasion being particularly sensitive to the adverse effects of stress [77]. As stress
levels are often high in pancreatic cancer patients [37–39] and metastatic dissemination is largely
responsible for cancer mortality [79,80], intervening in stress signaling may benefit pancreatic cancer
patients. Identification of β-adrenergic receptor signaling pathways as key regulators of the effects of
stress on pancreatic cancer progression suggests that β-blockers may be repurposed from their current
role as a cardiac medication to complement existing anti-cancer therapeutic strategies. Translation
of these preclinical findings will be guided by studies that clarify which β-blockers optimally target
the pancreatic tumor microenvironment and that characterize their mechanism of action. Translation
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will be additionally aided by stratifying patient sub-populations who will optimally benefit from
stress-reducing interventions.
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